share_log

JanOne's Subsidiary, Alt5, Reports 91% Year Over Year Increase in Transaction Volume to US $289 Million for April and May 2024

JanOne's Subsidiary, Alt5, Reports 91% Year Over Year Increase in Transaction Volume to US $289 Million for April and May 2024

JanOne旗下子公司Alt5報告稱,2024年4月和5月交易成交量同比增長91%,達到2.89億美元。
PR Newswire ·  06/13 19:30

LAS VEGAS, June 13, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, released today its wholly-owned subsidiary, ALT5 Sigma, transaction volume for April and May 2024.

2024年6月13日,拉斯維加斯 / PRNewswire / -- JanOne Inc.(納斯達克股票代碼:JAN)是一家專注於醫療保健和金融科技的多學科組織,今天發佈了其全資子公司 ALT5 Sigma 2024年4月和5月的交易成交量。

According to the Company, ALT5 Sigma transaction volume reached US$289 million for the months of April and May 2024 combined, compared to US$151 million in transaction volume for the months of April and May 2023 combined, representing a year-over-year increase of 91%.

公司表示,2024年4月和5月ALT5 Sigma的交易總成交量達到2.89億美元,而2023年4月和5月的交易成交量爲1.51億美元,同比增長了91%。

"Since inception, we have relied solely on word-of-mouth and client referrals to grow our business and have managed a steady growth year-over-year, and now we begin to roll out our global marketing strategies," said Andre Beauchesne, President of Alt5 Sigma. "The adoption of cryptocurrencies in many industries is accelerating and our B2B solutions can be easily integrated into all business processes from checkout to payouts," further added Mr. Beauchesne.

“自成立以來,我們一直僅依靠口碑和客戶推薦來發展業務。我們年復一年地保持了穩步增長,現在我們開始推出全球營銷策略,”ALT5 Sigma總裁Andre Beauchesne表示。“許多行業中加密貨幣的採用正在加速,我們的B2B解決方案可以輕鬆地集成到從結賬到支付的所有業務流程中,”Beauchesne先生進一步補充道。

About ALT5 Sigma Inc.

關於 ALT5 Sigma 公司

Launched in 2018, ALT5 is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5, through its subsidiaries, offers two main platforms to its customers: "ALT5 Pay" and "ALT5 Prime". The Company processed over US$1.2 billion in cryptocurrency transactions in 2023.

ALT5是一家成立於2018年的金融科技公司,提供下一代區塊鏈技術,以實現遷移到新的全球金融範式。ALT5通過其子公司向客戶提供兩個主要平台:“ALT5 Pay”和“ALT5 Prime”。該公司在2023年處理了超過12億美元的加密貨幣交易。

ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency (s) automatically or to receive their payment in digital assets.

ALT5 Pay是一種加密貨幣支付網關,可以使全球註冊和批准的商家接受和進行加密貨幣支付,或使用WooCommerce的插件或ALT5 Pay的結帳小部件和API集成ALT5 Pay支付平台到其應用程序或操作中。商家可以選擇自動轉換成法定貨幣或以數字資產接收付款。

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named "ALT5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers.

ALT5 Prime 是一種電子場外交易平台,使註冊和批准的客戶能夠買賣數字資產。客戶可以使用法定貨幣購買數字資產,同樣可以售出數字資產並收到法定貨幣。ALT5 Prime 透過一款名爲“ALT5 Pro”的基於瀏覽器訪問的手機應用程序進行訪問,該應用可以從蘋果應用商店中下載,從谷歌商店中下載,也可以通過 Broadridge 金融解決方案的 NYFIX 網關爲批准的客戶提供支持。

About JanOne

關於JanOne

JanOne is a unique Nasdaq-listed multidisciplinary organization with a focus on healthcare and fintech. JanOne is one of the constituents of the Russell Microcap Index, starting June 28, 2024. Through its biotech activities, JanOne is developing innovative, actionable solutions intended to help end the opioid crisis. JanOne is dedicated to funding resources toward innovation, technology, and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and most widespread in the nation's history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids.

JanOne是一個獨特的Nasdaq上市的多學科組織,專注於醫療保健和金融科技。JanOne是從2024年6月28日起加入Russell Microcap Index的成分之一。通過其生物技術活動,JanOne正在開發旨在幫助終結阿片類藥物危機的創新、可行的解決方案。JanOne致力於向創新、技術和教育的資金資源,爲國家阿片類藥物流行病找到一個重要解決方案。其臨床試驗產品線的藥物已經顯示出靶向疼痛原因的創新策略,是醫生們不願讓患者接觸成癮性阿片類藥物的戰略選擇之一。

JanOne's ALT5 subsidiary is a global fintech that provides next generation blockchain powered technologies for the trading, clearing, settlement, payment, and custodianship of digital instruments.

JanOne 的 ALT5 子公司是一家全球性金融科技公司,爲數字工具的交易、清算、結算、支付和保管提供下一代區塊鏈技術。

Please visit for additional information.

更多信息請訪問。

Forward Looking Statements

前瞻性聲明

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the statements that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope" "should", "would", "may", "potential", and other similar expressions. This press release also contains statements and links relating to the profitability and prospective growth of ALT5's platforms and business, including, but not limited to international currency risks, third-party or customer credit risks, liability claims stemming from Alt5's services, and technology challenges for future growth or expansion. Such statements reflect JanOne's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by JanOne, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies.

本新聞稿包含的聲明構成根據 1995 年《私人證券訴訟法》定義的前瞻性聲明,包括但不限於,關於JAN 101的PAD的治療效果、JAN 123的CRPS的治療效果、臨床試驗開始的時間,即FDA將允許通過505(b)(2)途徑批准JAN 123,即當JAN101獲批後,將立即顛覆PAD市場的聲明等。本新聞稿還包含與ALT5平台和業務的盈利能力和前景增長有關的聲明和鏈接,包括但不限於國際貨幣風險,來自Alt5服務的第三方或客戶信貸風險,以及未來增長或擴展的技術挑戰。這些語句反映了JanOne 對未來事件的當前看法,受到風險和不確定性的影響,並且基於一些估計和假設,儘管這些估計和假設被JanOne認爲是合理的,但這些假設本質上是受到重大商業、經濟、競爭、政治和社會不確定性和突發事件和突發情況的影響。

Many factors could cause JanOne's actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in JanOne's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and JanOne does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. JanOne cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

許多因素可能導致JanOne的實際結果,表現或成就與本新聞稿中描述的任何未來結果,表現或成就有實質不同。 諸如這些風險或不確定性之一的因素可能包括那些在公司向美國證券交易委員會(SEC)提交的定期報告中詳細描述的風險。如果這些風險或不確定因素之一實現,或者在JanOne提交給SEC的文件中所述的"風險因素"部分所述的假設爲錯誤的,那麼實際結果可能會有所不同。這些前瞻性聲明是根據本新聞稿發佈的日期製作的,JanOne並不打算,並且不承擔任何義務更新這些前瞻性聲明,除非法律要求。JanOne無法保證此類聲明將被證明是準確的,因爲實際結果和未來事件可能與此類聲明預期的結果有所不同。由於存在固有的不確定性,因此告知投資者不要過度依賴前瞻性聲明。

Media Contact Investor Relations
[email protected]
1-800-400-2247

媒體聯繫投資者關係
[email protected]
1-800-400-2247

SOURCE JanOne Inc.

SOURCE JanOne Inc.

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論